ECR 2013 Rec: MR spectroscopy in mild and moderate cognitive impairment as illness outcome predictor: preliminary experience #SS611 #B0403
B-0403 MR spectroscopy in mild and moderate cognitive impairment as illness outcome predictor: preliminary experience
J. Forner Giner, A. Alberich-Bayarri, G. Garcia Marti, A. Pomar-Nadal, J. Rayón-Aledo, L. Martí-Bonmatí | Friday, March 8, 14:00 – 15:30 / Room B
Purpose: To evaluate Alzheimer’s disease premature diagnosis based on spectroscopy MRI.
Methods and Materials: We carried out a prospective study on 178 patients (116 women and 62 men) whose ages ranged 27 to 68 years (mean age 65 ± 12). Every patient presented mild or moderate cognitive impairment according to Reisberg score (3-4 grade). Standard brain MR and spectroscopy brain MR were performed using a 3 T intensity MRI device (Archieva TX, Philips Healthcare, Best, The Netherlands). Spectroscopy MR was focused in posterior parietal and frontal lobes gray substance using a unique volume (20 x 20 x 15 mm) and two different echo-times, TE (32 and 136). Morphology and volume of temporal lobes were evaluated through FLAIR coronal images which were used to quantify temporal horn width and so classify patients in four groups. JMRUI (Java Magnetic Resonance User Interface) was used to calculate quantitative parameters in MR spectroscopy. MR was used to measure: calculation of NAA (N-acetyl aspartate), Cr (creatinine), Cho (choline) and mI (myo-inositol) metabolites ratios. We used analysis of variance to compare metabolite ratios between the different patient groups previously defined.
Results: We found significant differences (p ≤ 0,05) between groups in NAA/Cho concentration (p=0,022), both in long and in short eco times and frontal and parietal anatomical regions. No other significant differences between groups were found.
Conclusion: MR spectroscopy could increase efficiency in Alzheimer’s disease premature diagnosis as well as turning out to be a useful additional tool for the clinician next to clinical history.
